Insulin Pumps, Continuous Glucose Monitors, Closed Loop Insulin Delivery Systems and Associated Products

Description

It is the intention for the following to be available under the terms of the Framework Agreement: Tethered Insulin Pumps, Patch Insulin Pumps, Continuous Glucose Monitoring (CGM) devices, Applications or software to enable the function of Closed Loop Insulin Delivery Systems and also for the dedicated consumables and accessories for the products listed above. Due to technological advancement, specifications will be reviewed. To enable the NHS to access to the latest products via the framework, new suppliers may be awarded to the current Framework Agreement, which was launched in January 2022 and will run for an initial 24 month period, and may be extended up to a total of 48 months. Precise quantities are unknown. It is anticipated that annual expenditure will be in the region of £15,000,000 - £20,000,000, however this is approximate only and the values may vary depending on the requirements of those bodies purchasing under the Framework Agreement. Estimated total value over the 4 year agreement is approximately £75,000,000 to £100,000,000. Lot Lot 1: Insulin Pumps This lot is for Standalone Insulin Pumps and also Tethered Insulin Pumps, Patch Insulin Pumps, Tethered Pump with Integrated Continuous Glucose Monitor, Patch Pumps with Integrated Continuous Glucose Monitor, Tethered Pump with Integrated Continuous Glucose Monitor and Algorithm. This Lot also includes, but is not limited to; Insulin subcutaneous infusion set Tubes Cannula’s Needle cartridges Handsets Insertion Devices Adaptors Batteries Carry Cases Belts Remotes Sensors Finger Prickers Battery caps Resevoirs USB Adapters Clips Luer Locks Dressings Pouches Service packs Any other option or accessory used with or to configure the pumps Additional information: Anticipated expenditure will be circa £18,000,000 for the two years of this Framework Agreement, this is approximate and may vary depending on the requirements of bodies purchasing under the agreement.For the full 48 month term (if extended) the anticipated value is circa £36,000,000. These values are approximate, based on historical usage information, with a forecasted level of growth. Lot Lot 2: Continuous Glucose Monitors This lot is for standalone CGM and Flash Glucose Monitoring. This Lot also includes Receivers, Transmitters, Sensors and Flash Glucose Monitoring Devices. This lot includes but is not limited to: Handsets Sensors Carry cases Tapes Finger prickers Clips Dressings Adhesives Insertion devices Testers Service Packs Download Features Any other option or accessory used to configure the unit Additional information: Anticipated expenditure will be circa £7,500,000 for the two years of this Framework Agreement, this is approximate and may vary depending on the requirements of bodies purchasing under the agreement.For the full 48 month term (if extended) the anticipated value is circa £14,500,000. These values are approximate, based on historical usage information, with a forecasted level of growth. Lot Lot 3: Software and Diabetes Management Systems This lot is for Applications, Software or Alogrithms that contribute to the functionality of a Closed/Semi Closed Loop Insulin Delivery System and Diabetes Management Systems that allow for the uploading of information from Insulin Pumps, CGM’s, Glucose Meters and/or Mobile Applications. Mobile applications that act only as an Insulin Pump or CGM controller must not be included in this lot and must instead be submitted as an accessory in the relevant lot where the Pump or CGM device sits. Additional information: Anticipated expenditure will be circa £6,000,000 for the two years of this Framework Agreement, this is approximate and may vary depending on the requirements of bodies purchasing under the agreement.For the full 48 month term (if extended) the anticipated value is circa £12,000,000. These values are approximate, based on historical usage information, with a forecasted level of growth.